+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Oligonucleotide Synthesis Industry Research Analysis

25 July 2020

Visiongain has launched a new report Oligonucleotide Synthesis Market Forecast 2020-2030: Forecasts and Analysis by Product (Probe, Linkers, Adaptor, Drugs, Reagent, Equipment), Type (Custom, Pre Design), Application (PCR, DNA, RNAi, Research, Therapeutic), End User (Hospital, Pharmaceutical, Biotechnology) and Geography, with Profiles of Leading Companies.

According to the report published by Visiongain, the Oligonucleotide Synthesis market is estimated to be valued at approximately USD 4.5 billion in 2019 and is expected to generate around USD 11.2 billion by 2030, at a CAGR of around 14.7% between 2020 and 2030. Almost every molecular biologic technique used nowadays involves chemical synthesized PCR, Real-Time PCR, site-driven mutagenesis, single-core polymorphism (SNP) tests, microarrays and a rapidly increasing world of small RNAs. Similarly, PCRs are used in almost all molecular biology technologies. Furthermore, in addition to other reagents the oligonucleotide is custom made and cleaned in compliance with the specific needs of the particular researcher, as expected. In the last few years, development has culminated over major performance and production improvements and significant cost savings in the fields of olegonucleotide synthesis, purification and quality control. At the same period, oligonucleotide production has contributed to a drastic rise in the number of modifications usable. The developments in oligonucleotide synthesis, purification and QC have also culminated in the development of high quality products in the wide range of possible syrtheses, such as those found in the integrated DNA technologies, provided that technological advances have led for applications to high performance testing.

Oligonucleotide Synthesis Market is witnessing Growth due to factors such as
The oligonucleotide synthesis demand has increased as a result of increased government spending, research and development expenses on pharmaceutical and biotechnology firms and the use of synthesized oligonucleotides for molecular and medical diagnostics. Thanks to several advantages of molecular diagnostics and increasing medical uses, the use of artificial oligonucleotides has increased rapidly in the last decade. The techniques of nucleic acid application are a benchmark and very useful for molecular diagnosis in various diseases such as hepatitis. for the detection of infectious diseases. Significant medical uses are also available for artificial oligonucleotides, especially for automobile antibodies. Synthetic biology in recent years has been constantly developing, utilizing artificial oligonucleotides to check the identification of anti-double stranded DNAs. Thus, the oligonucleotide synthesis sector is accountable for all these reasons.

In addition, the market for oligonucleotide synthesis is also influenced by others. In this context, it is expected to grow in the Oligonuc forecast period, which includes growing advances in the healthcare field, increasing demand for innovation in life sciences and medical academics, increasing government investment in the development of genomic technologies and the increasing demand for oligonucleotide synthesis technologies by public and private probes.

Synthesis of oligonucleotides is an important part of several recent experiments in genetics
Decreasing sequencing costs have contributed to increasing demand in science, genetic testing, drug development and forensic applications of custom-made nucleotides for desirable series. In turn, this promoted demand in the various life-science industries for oligonucleotides synthesis. Custom synthesis requests from various classes of oligos including decoies, aptamers and immuno-stimulants, antisense, siRNA and miRNA are projected to increase investment in genetic research. Most big and small suppliers of oligonucleotides grow their market by partnering with drug manufacturers. CordenPharma International, for instance, formed a strategic partnership with GE Healthcare Dharmacon Inc. in June 2017 to establish an end-to-end drug discovery approach for oligonucleotides.

Late clinical trials addressing various conditions, for instance diabetes, heart problems, muscular dystrophies and eye defects are being performed with a substantial number of oligos. This anticipated regulatory approval is expected to promote the market for multiple oligonucleotide based therapies. Direct sales and sales through distributors in specific countries are part of marketings implemented in this market. The market is expected to benefit from constant growth in the genomics and genetic modification markets as progress in genetic instruments simplifies oligonucleotide synthesis.

Introduction of New and Robust Synthesizers
The segment is driven by the introduction of new and robust synthesizers which permit the quick and large-scale production of long oligonucleotide sequences. However, contract-manufacturing and consulting services have increased due to various contract-service provider advantages including improved efficiency, cost-effective services and quick product development. The segment of services is projected to promote growth. A vast array of reagents has contributed significantly to the prevailing proportion of detrityisation / deblocking, corrosion, cleavages, purification / desalting, marking and alteration of oligonucleotides. The segment is also fueled by the need for specific reagents at each step of synthesis and high cost.

PCR Primers Have Enjoyed The Highest Share Of Revenue In Oligonucleotide Synthesis
For target testing and detection, PCR primers are commonly used for drug development. In various stages of clinical development, PCR primers have enjoyed the highest share of revenue in oligonucleotide synthesis, thanks to the robust pipelines of oligonucleotide-based therapeutics, including the antidisaster treatment industry, DNA vaccine, and anti-viral agents.

Increasing reliance on selective gene therapies has revolutionized the care for genetically modified incurable diseases. Manufacturers have seen an increase in demand for clinical, diagnostic, academic and pharmaceutical sequencing applications.

Shift in Trends

Government and Private Entities Are Investing In The Development Of Emerging Economies ' Academic And Research Infrastructure
The focus is on the research of alternative approaches to treating diseases by the pharmaceutical industry and the biotechnology companies. As a consequence, oligonucleotides are used by these companies as they provide an efficient way of treating different signs at comparatively low development cost. Moreover, the challenge of the efficient way of administration of drugs involves oligonucleotides. This, in turn, will increase oligonucleotide therapy production and increase the share of pharmaceutical and biotechnology firms on the global market.

Government and private entities are investing in the development of emerging economies ' academic and research infrastructure. This will increase oligonucleotide adoption in research institutes positive. This factor is expected to be positive. The increase in genomic research projects carried out by academic research institutes has made it possible for this segment to take the dominant market share account. Moreover, the creation of novel approaches to cure of chronic conditions through genetic medicine would contribute to the growth of this segment through the involvement of major players and universities.

Increased market potential permits for pipeline products
In all step clinical studies, the largest proportion of oligonucleotides are used for multiple diseases such as cancer, muscular dystrophy, heart and eye disorders. The growth of the global oligonucleotide synthesis market is expected to result in growing regulatory approvals for multiple therapies especially based on oligonucleotides. Advanced strategy targeting the marketing and adoption including the improvement of direct sales and distributors in particular developing countries. However, oligonucleotide advantages and the success of its synthesis are driving an increase in the global synthesis market for oligonucleotides.

Regional Market Analysis

Regional Market Outlook
Innovation and key players in the United States have brought about greater market penetration of products. In 2017, North America was therefore liable for a large portion in sales. In contrast, Northern America has played significantly in sustaining a significant share in gene, proteomics, oncology, medical testing, and drug discovery.

Due to the rapid progress in genomics studies and the healthcare industry, asian countries are the quickest adopters of sequence, spectrum technology and PCR products. As far as expansion or growth opportunities in those countries are concerned, Japan and China are considered the most attractive markets. However, the new economic environment has enabled global players to join the Asia-Pacific market with significant investments in healthcare, life-science programs, and genetics and thus continued to expand them.

Top Companies
Kaneka Eurogentec S.A.
Biolegio B.V.
Eurofins Scientific SE
Bioneer Corporation
Kaneka Corporation (Eurogentec)
Eton Bioscience, Inc.
Agilent Technologies
Bioautomation (Acquired By LGC)
Bio-Synthesis Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033

31 May 2023


Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.

26 May 2023


Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033

24 May 2023


Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033

23 May 2023